Famitinib
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroenteropancreatic Neuroendocrine Tumor
Conditions
Gastroenteropancreatic Neuroendocrine Tumor
Trial Timeline
Oct 1, 2011 → May 1, 2016
NCT ID
NCT01994213About Famitinib
Famitinib is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Gastroenteropancreatic Neuroendocrine Tumor. The current trial status is terminated. This product is registered under clinical trial identifier NCT01994213. Target conditions include Gastroenteropancreatic Neuroendocrine Tumor.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05473468 | Phase 1 | UNKNOWN |
| NCT04479904 | Phase 2 | Withdrawn |
| NCT01762293 | Phase 2 | Completed |
| NCT02336724 | Phase 2 | UNKNOWN |
| NCT01994213 | Phase 2 | Terminated |
| NCT01392235 | Phase 2 | Completed |
Competing Products
9 competing products in Gastroenteropancreatic Neuroendocrine Tumor
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide. | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| 68Ga-DOTATOC | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Lanreotide + Pembrolizumab | Merck | Phase 1/2 | 41 |
| Lutathera + Gallium 68 Dotatate | Novartis | Phase 1 | 33 |
| Lutathera® | Novartis | Pre-clinical | 23 |
| Pasireotide LAR followed by Pasireotide LAR + Everolimus + Everolimus followed by Pasireotide LAR + Everolimus | Novartis | Phase 1 | 33 |
| Lanreotide Autogel 120 mg + Temozolomide (TMZ) | Ipsen | Phase 2 | 49 |
| satoreotide trizoxetan | Ipsen | Phase 1/2 | 38 |
| Lanreotide autogel | Ipsen | Phase 3 | 74 |